You are here: Home » Current Affairs » Coronavirus » News
Business Standard

First Covid-19 vaccine to reach phase-1 trial is safe, say researchers

Several teams across the world are in a race to develop a vaccine for coronavirus infection

Coronavirus | Vaccine | Lockdown


The scientists said these cells then produce the spike protein, and travel to the lymph nodes where the immune system creates antibodies

Days after US drugmaker Moderna claimed that the phase-1 trial of its Covid-19 has shown positive results, a new research published in The Lancet journal on Friday reported that vaccine, the first to reach phase-I clinical trial, is safe, well-tolerated, and capable of generating an immune response against the novel in humans.

The trial was conducted by researchers at several laboratories and included 108 participants aged 18-60. The produced neutralising antibodies and a response mediated by the immune system's T-cells against the novel coronavirus, SARS-CoV-2.

Several teams across the world are in a race to develop a vaccine, considered to be the most effective solution for coronavirus, which has claimed more than 300,000 lives worldwide.

A report in The New York Times that cited the early-stage trial published in online journal Lancet, said those who received a single dose of the produced certain immune cells, called T-cells, within two weeks while the antibodies needed for immunity peaked 28 days after the inoculation.

ALSO READ: China's Covid-19 vaccine shows promising results in early trials: Report

However, the scientists, including those from the Beijing Institute of Biotechnology in China said further research is needed to confirm whether the vaccine protects against SARS-COV-2 infection. In the trial, carried out in 108 healthy adults, the vaccine demonstrated promising results after 28 days, with the final results to be evaluated in six months, the study said.

"These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored Covid-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days," said study co-author Wei Chen from the Beijing Institute of Biotechnology.

Based on the results, Chen said the vaccine is a potential candidate for further investigation. However, the researchers cautioned that the results should be interpreted carefully.

"The challenges in the development of a COVD-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from Covid-19," Chen explained.

ALSO READ: Britain's AstraZeneca to make bn Covid-19 vaccine doses if tests succeed

The Ad5 vectored Covid-19 vaccine used in the trial is the first to be tested in humans, the scientists said. It uses a weakened common cold-causing adenovirus -- which infects human cells readily, but is incapable of causing -- to deliver genetic material that codes for the SARS-CoV-2 spike protein to the cells, the study noted.

The scientists said these cells then produce the spike protein, and travel to the lymph nodes where the immune system creates antibodies. These then recognise the spike protein and fight off the coronavirus, the researchers explained.

In the trial, they assessed the safety and ability of the new Ad5-nCoV vaccine to generate an immune response of different dosages in 108 healthy adults between the ages of 18 and 60 years. The volunteers were assigned to receive either a single injection of the new Ad5 vaccine at a low dose, middle dose, or a high dose, they said.

According to the study, the volunteers' blood was checked at regular intervals following vaccination to see whether the vaccine stimulated two parts of the immune system. These are the body's humoral response', which is the part of the immune system that produces antibodies to fight infection, and the 'cell-mediated' arm, which depends on a group of T cells to fight the virus, the scientists said.

ALSO READ: Oxford University's candidate for coronavirus vaccine fails animal tests

They added that an ideal vaccine candidate generates both antibody and T cell responses to defend against SARS-CoV-2. Based on the results, the researchers said the vaccine was well tolerated by the volunteers at all doses with no serious adverse events reported within 28 days of vaccination.

They said most adverse events were mild or moderate, with 83 per cent of those receiving low and middle doses of the vaccine and 75 per cent in the high dose group reporting at least one adverse reaction within 7 days of vaccination.

These reactions were mild pain at the injection site reported in over half of vaccine recipients, fever in 50 per cent of them, fatigue, headache, and muscle pain as well. Within two weeks of vaccination, the study noted that all dose levels of the vaccine triggered some level of immune response. Some of the participants, the researchers said, also exhibited a form of neutralising antibodies against SARS-CoV-2.

ALSO READ: Covid-19: Total 8 vaccine candidates are in clinical trial stage, says WHO

After 28 days, they said most participants had a four-fold increase in binding antibodies. The scientists also added that 50 per cent of the participants in the low- and middle-dose groups, and three-quarters of those in the high-dose group showed neutralising antibodies against SARS-CoV-2.

In the majority of volunteers, they said the vaccine also stimulated a rapid T cell response. On further analyses, the researchers said the majority of recipients showed either a positive T cell response, or had detectable neutralising antibodies against SARS-CoV-2 as much as 28 days after vaccination.

However, they said high pre-existing immunity to adenovirus type 5 -- the common cold virus vector used in the study, may have reduced both the antibody and T-cell response in the participants.

"Our study found that pre-existing Ad5 immunity could slow down the rapid immune responses to SARS-CoV-2 and also lower the peaking level of the responses," said Feng-Cai Zhu from the Jiangsu Provincial Center for Control and Prevention in China, who led the study.

Citing the main limitations of the trial, the authors said the study had a small sample size and was conducted in relatively short duration, with a lack of randomised control group.

They said further research will be needed before this trial vaccine becomes available to all.

First Published: Sat, May 23 2020. 13:30 IST